-Economic and Political Weekly A report on the 2013 deliberation of the Kolkata Group at its 10th workshop which focused on healthcare, the status of women and social justice in India. A K Shiva Kumar (akshivakumar@gmail.com) is convener of the Kolkata Group workshops which are organised by Pratichi (India) Trust, the Harvard Global Equity Initiative and UNICEF India. At the 10th annual Kolkata Group workshop in February this year, 40 policymakers, development practitioners,...
More »SEARCH RESULT
Total Matching Records found : 3277
Aruna Roy, social activist and NCPRI member interviewed by Pallavi Polanki
-Firstpost.com After the UPA-II released its self-congratulatory 79-page ‘Report card to the People', National Advisory Council (NAC) member and leading social activist Aruna Roy has come down heavily on the government for its poor performance in the social sector. Roy, an instrumental force behind the Right to Information Act, criticised the government for stalling on essential legislations such as the Food Security Bill, the Land Acquisition Bill and the Lokpal Bill. Roy spoke...
More »The right medicine
-The Business Standard Govt should streamline its free medicines plan The Centre is reportedly going to shelve a plan to procure generic drugs for free supply to patients throughout the country. This is a serious error. Reportedly, states will instead be asked to do so; but, if a perceived inability to procure, stock and distribute these drugs is the reason for backtracking on the plan, how precisely will states be free of...
More »Does Sahara group come under RTI Act? Sebi gets a query!
-PTI MUMBAI: A long-drawn case involving funds raised by two Sahara firms through 'various illegalities' seems to have made Sebi a preferred agency for all kinds of queries about the group, with the latest being whether the Lucknow-based conglomerate falls under the purview of RTI Act. After Sebi rejected the information sought from it through an RTI (Right to Information) application in this regard, the appellant approached the Appellate Authority but the...
More »USFDA scrutiny: Will pharma majors like Ranbaxy, Wockhardt be affected in long-term? -G Seetharaman
-The Economic Times Japanese companies do not mind erring on the side of caution. They are known to think longer and harder than their counterparts in other countries about big decisions, especially when it comes to entering a new market or acquiring a foreign company. But Japan's third biggest drugmaker Daiichi Sankyo would now wish it had spent more time doing due diligence on Ranbaxy Labs, in which it bought a...
More »
